TCL Archive Niederhuber says his job is easy, but times are hard: NCI may need to cut up to $150 million. December 9, 2005
TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
